Free Trial
NASDAQ:CANC

Tema Oncology ETF (CANC) Price, Holdings, & News

$27.62
-0.27 (-0.97%)
(As of 10/31/2024 ET)

About Tema Oncology ETF (NASDAQ:CANC)

Key Stats

Today's Range
$27.50
$27.88
50-Day Range
$27.54
$29.87
52-Week Range
$21.70
$30.11
Volume
1,494 shs
Average Volume
6,952 shs
Market Capitalization
$48.06 million
Assets Under Management
$48.51 million
Dividend Yield
0.51%
Net Expense Ratio
0.75%
Aggregate Rating
Moderate Buy

ETF Overview

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.

Tema Oncology ETF Expenses

TypeCANCTheme ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.99%0.57%0.55%0.49%0.52%
Other Expenses0.00%0.57%0.49%0.41%0.53%
Total Expense0.99%0.73%0.71%0.63%0.71%
Fee Waiver-0.24%-0.74%-0.52%-0.32%-0.57%
Net Expense0.75%0.59%0.61%0.56%0.59%
Receive CANC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tema Oncology ETF and its competitors with MarketBeat's FREE daily newsletter.

CANC ETF News Headlines

No headlines for this company have been tracked by MarketBeat.com

CANC ETF - Frequently Asked Questions

Tema Oncology ETF's stock was trading at $26.40 at the start of the year. Since then, CANC shares have increased by 4.6% and is now trading at $27.6212.
View the best growth stocks for 2024 here
.

Shares of CANC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Oncology ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NICE (NICE) and Intellia Therapeutics (NTLA).

Fund Details

Issuer
Tema Global
Fund Name
Tema Oncology ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:CANC
Inception Date
8/15/2023
Fund Manager
David Song
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Developed Markets
Region
Global
Number of Holdings
52

Fund Statistics

Assets Under Management
$48.51 million
Average Daily Volume
$0.00
Discount/Premium
0.01%

Administrator, Advisor and Custodian

Administrator
US Bancorp Fund Services, LLC
Advisor
Tema Global Limited
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
N/A
Short Interest
1,600 shs

Miscellaneous

Beta
1.11
Creation Unit
10,000
Creation Fee
$500.00
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Top 10 CANC Holdings

CANC Sector Exposure

CANC Industry Exposure


This page (NASDAQ:CANC) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners